BR112022011810A2 - Compostos inibidores de oga - Google Patents

Compostos inibidores de oga

Info

Publication number
BR112022011810A2
BR112022011810A2 BR112022011810A BR112022011810A BR112022011810A2 BR 112022011810 A2 BR112022011810 A2 BR 112022011810A2 BR 112022011810 A BR112022011810 A BR 112022011810A BR 112022011810 A BR112022011810 A BR 112022011810A BR 112022011810 A2 BR112022011810 A2 BR 112022011810A2
Authority
BR
Brazil
Prior art keywords
compounds
oga
compositions
inhibitor compounds
relates
Prior art date
Application number
BR112022011810A
Other languages
English (en)
Inventor
Manuel Bartolomé-Nebreda José
Jacobus Johannes Antonius Buijnsters Petrus
Isabel De Lucas Olivares Ana
Elisabeth Leenaerts Joseph
Martinez Lamenca Carolina
Oehlrich Daniel
Avelino Trabanco-Suárez Andrés
Emiel M Van Roosbroeck Yves
Ingrid Velter Adriana
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022011810A2 publication Critical patent/BR112022011810A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS INIBIDORES DE OGA. A presente invenção refere-se a inibidores de O-GlcNAc hidrolase (OGA). A invenção também se refere a composições farmacêuticas compreendendo tais compostos, a processos para preparar tais compostos e composições e ao uso de tais compostos e composições para a prevenção e tratamento de distúrbios nos quais a inibição de OGA é benéfica, tais como tauopatias, em particular, doença de Alzheimer ou paralisia supranuclear progressiva; e doenças neurodegenerativas acompanhadas por uma patologia de tau, em particular, esclerose lateral amiotrófica ou demência do lobo frontotemporal causada por mutações C9ORF72.
BR112022011810A 2019-12-18 2020-12-18 Compostos inibidores de oga BR112022011810A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19383138 2019-12-18
EP20197523 2020-09-22
EP20203022 2020-10-21
PCT/EP2020/087201 WO2021123294A1 (en) 2019-12-18 2020-12-18 Oga inhibitor compounds

Publications (1)

Publication Number Publication Date
BR112022011810A2 true BR112022011810A2 (pt) 2022-08-30

Family

ID=74130209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011810A BR112022011810A2 (pt) 2019-12-18 2020-12-18 Compostos inibidores de oga

Country Status (11)

Country Link
US (1) US20230099293A1 (pt)
EP (1) EP4077323A1 (pt)
JP (1) JP2023507184A (pt)
KR (1) KR20220118483A (pt)
CN (1) CN114867725A (pt)
AU (1) AU2020409728A1 (pt)
BR (1) BR112022011810A2 (pt)
CA (1) CA3160405A1 (pt)
IL (1) IL293931A (pt)
MX (1) MX2022007654A (pt)
WO (1) WO2021123294A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202346267A (zh) 2022-03-07 2023-12-01 美商安進公司 用於製備４－甲基－２－丙－２－基－吡啶－３－甲腈之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2174746A1 (en) * 1972-03-09 1973-10-19 Anvar 1-methyl-4-anlino-5-aza indoles - antiinflammatories
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
ES2723883T3 (es) 2013-03-14 2019-09-03 Merck Patent Gmbh Inhibidores de glicosidasa
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
EP3186243B1 (en) 2014-08-28 2021-07-21 Asceneuron SA Glycosidase inhibitors
WO2017106254A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
DE102015122932A1 (de) 2015-12-29 2017-06-29 fos4X GmbH Verfahren zum Prognostizieren der Anlagerung von Eis an einem Rotorblatt einer Windkraftanlage und dessen Verwendung
WO2017144637A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Acid addition salts of piperazine derivatives
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
CN110312716A (zh) * 2016-12-16 2019-10-08 詹森药业有限公司 双环oga抑制剂化合物
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
TWI669302B (zh) 2017-05-25 2019-08-21 美商美國禮來大藥廠 5-甲基-1,3,4-<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>二唑-2-基化合物
CA3093315A1 (en) 2018-03-14 2019-09-19 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors

Also Published As

Publication number Publication date
EP4077323A1 (en) 2022-10-26
CA3160405A1 (en) 2021-06-24
KR20220118483A (ko) 2022-08-25
CN114867725A (zh) 2022-08-05
MX2022007654A (es) 2022-07-19
WO2021123294A1 (en) 2021-06-24
JP2023507184A (ja) 2023-02-21
US20230099293A1 (en) 2023-03-30
AU2020409728A1 (en) 2022-08-11
IL293931A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MA53937B1 (fr) Compositions comprenant des souches bactériennes
BR112013022039A2 (pt) derivados 6,7-di-hidro-pirazol[1,5-a]pirazin-4-ilamina úteis como inibidores de beta-secretase (bace)
TN2017000144A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
BR112016017344A2 (pt) Amidas de heteroaril como inibidores de agregação de proteínas
JO3459B1 (ar) تركيبات صيدلانية لعلاج مرض الزهايمر
SA114360153B1 (ar) مركبات واستخدامها كمثبطات bace
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
TN2017000134A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer&#39;s disease
BR112012033291A2 (pt) derivados de 3-amino-5,6-di-hidro-1h-piranzin-2-ona úteis para o tratamento de doença de alzheimer e outras formas de demência
BR112012031337A2 (pt) derivados de 5-amino-3,6-di-hidro-1h-pirazin-2-ona úteis como inibidores de beta-secretase (bace)
EA201291435A1 (ru) Производные 5,6-дигидро-2h-[1,4]оксазин-3-иламина в качестве ингибиторов бета-секретазы (bace)
ATE511843T1 (de) Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz
MX2012006730A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
EA201190020A1 (ru) Производные изоиндола в качестве ингибиторов васе и их применение
MX2014006752A (es) Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina.
MX2010004319A (es) Compuesto de alfa-(n-sulfonamido)acetamida novedoso como un inhibidor de producccion de peptido beta amiloide.
BR112012021656A2 (pt) composto, uso do mesmo, e, composição farmacêutica
BR112021006319A2 (pt) compostos de indolinona para uso como inibidores de map4k1
MX2017008083A (es) Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.
BR112022011810A2 (pt) Compostos inibidores de oga
BR112022011812A2 (pt) Compostos inibidores da oga
MX2018003565A (es) Derivados de 2,3,4,5-tetrahidropiridin-6-amina.
PH12017501668A1 (en) Bace1 inhibitors
MA54630B1 (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives
EA201992188A1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов